A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database.

Ajay Sharma Paula J Alvarez Steven D Woods Dingwei Dai

Published in: ClinicoEconomics and outcomes research : CEOR (2020)

Guideline-recommended doses of RAASi therapy can be limited by the risk of HK. Novel potassium binders may permit more patients at risk to benefit from these maximal RAASi doses. This predictive model successfully identified the risk of developing HK up to 1 year in advance.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
health insurance
emergency department
patient reported outcomes
stem cells
resistance training
patient reported
replacement therapy
cell therapy